LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and
EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered 9.9% reported and 10.0% constant-currency revenue growth
– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance (1) – Achieved a key milestone in scaling oxygenator production capacity with the operational launch of a dedicated manufacturing line
GLOUCESTER, United Kingdom, November 4, 2026 — LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights (1)
• Third-quarter revenue of $393.1 million increased 9.9% on a reported basis and 10.0% on a constant-currency basis as compared to the prior-year period
• Third-quarter U.S. GAAP diluted earnings per share of $0.11 and adjusted diluted earnings per share of $1.23
• Third-quarter net cash provided by operating activities of $73.7 million and adjusted free cash flow of $55.8 million
• Raised full-year 2026 revenue growth range by 100 basis points to 9% to 10% on a constant-currency basis. Raised full-year 2026 adjusted diluted earnings per share range by $0.10 at midpoint to $4.40 to $4.50. Maintained full-year 2026 adjusted free cash flow range of $140 million to $160 million
• Achieved operational production on previously announced new oxygenator manufacturing line, representing an important milestone in expanding production capacity to address strong customer demand
• In October 2026, the American Medical Association CPT® Editorial Panel announced the establishment of new Category I Current Procedural Terminology (CPT®) codes that include LivaNova’s proximal hypoglossal nerve stimulation therapy for the treatment of moderate to severe obstructive sleep apnea, with an expected effective date of January 1, 2028
• In October 2026, announced the publication of the full 36-month results from the CORE-VNS study, the largest prospective, international study evaluating contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy, in Neuromodulation demonstrating a 76% median reduction in seizure frequency and a durable clinical benefit
(1) Constant-currency percent change, adjusted diluted earnings per share, and adjusted free cash flow are non-GAAP measures. Constant-currency percent change excludes the impact from fluctuations in the various currencies in which the Company operates as compared to reported percent change. For an explanation of these and other non-GAAP measures used in this news release, see the section entitled "Use of Non-GAAP Financial Measures." For reconciliations of certain non-GAAP measures, see the tables that accompany this news release. As discussed in the section entitled "Use of Non-GAAP Financial Measures" below, the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Accordingly, the Company is unable to reconcile forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts. 1 “Our team continues to deliver robust revenue growth driven by commercial execution and healthy global demand for our Cardiopulmonary and Epilepsy technologies,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “We also made meaningful progress against key milestones, positioning us to address significant market demand while expanding patient access to care. Our updated 2026 guidance reflects confidence across the portfolio as we advance our strategic priorities, drive innovation to address important unmet patient needs, and remain focused on delivering long-term shareholder value.” Third-Quarter 2026 Results The following table summarizes net revenue by segment (in millions):
(1) “Other revenue” includes rental and site services income not allocated to segments. In addition, for 2025, “Other revenue” includes $3.1 million from a reduction in the reserve associated with the Italian MedTech payback measure related to product sales of previously divested businesses.
Third-quarter 2026 Cardiopulmonary revenue increased 10.9% on a reported basis and 10.9% on a constant-currency basis versus the third quarter of 2025 with growth across all regions, driven by strong consumables demand and Essenz™ Perfusion System sales, as well as favorable realized price.
Third-quarter 2026 Neuromodulation revenue increased 11.1% on a reported basis and 11.2% on a constant-currency basis versus the third quarter of 2025 with growth across all regions, driven by higher volume and favorable realized price.
On a U.S. GAAP basis, third-quarter 2026 operating income was $28.4 million, as compared to operating income of $54.0 million for the third quarter of 2025. Adjusted operating income for the third quarter of 2026 was $92.3 million, as compared to adjusted operating income of $80.4 million for the third quarter of 2025.
On a U.S. GAAP basis, third-quarter 2026 diluted earnings per share was $0.11 as compared to diluted earnings per share of $0.49 in the third quarter of 2025. Third-quarter 2026 adjusted diluted earnings per share was $1.23, as compared to adjusted diluted earnings per share of $1.11 in the third quarter of 2025. 2 Full-Year 2026 Guidance
LivaNova now expects full-year 2026 revenue to grow between 9% and 10% (versus 8% and 9% prior) on a constant-currency basis. Foreign currency is expected to be a tailwind of approximately 1% based on current exchange rates, consistent with prior guidance.
Adjusted diluted earnings per share for 2026 is now expected to be in the range of $4.40 to $4.50 (versus $4.30 to $4.40 prior), assuming a share count of approximately 56 million for full-year 2026. In 2026, the Company estimates adjusted free cash flow in the range of $140 million to $160 million, consistent with prior guidance.
As discussed in the section entitled “Use of Non-GAAP Financial Measures” below, the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Accordingly, the Company is unable to reconcile the forward-looking non-GAAP financial measures included in this section to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts.
The Company will host a live audiocast at 1 p.m. London time (8 a.m. Eastern Standard Time) on Wed., November 4, 2026 that will be accessible at www.livanova.com/events . Listeners should register in advance and log on approximately 10 minutes early to ensure proper setup. To listen to the conference call by telephone, dial +1 833 461 5787 (if dialing from within the U.S.) or +1 585 542 9983 (if dialing from outside the U.S.). The conference call meeting ID is 495924914. Within 24 hours of the audiocast, a replay will be available at www.livanova.com/events , where it will be archived and accessible for approximately 90 days.
LivaNova PLC is a global medical technology company built on nearly five decades of experience with a vision to change the trajectory of lives for a new day. Through ingenious medical solutions in select neurological and cardiac conditions, LivaNova strives to ignite patient turnarounds. With its registered office in the United Kingdom, approximately 3,300 employees, and a presence in more than 100 countries, LivaNova serves patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com . 3 Use of Non-GAAP Financial Measures To supplement financial measures presented in accordance with generally accepted accounting principles in the United States (U.S. GAAP or GAAP), management has disclosed certain additional measures not presented in accordance with GAAP known as “non-GAAP financial measures” or “adjusted financial measures.” Company management uses these non-GAAP measures to monitor the Company’s operational performance and for benchmarking against other medical technology companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, operational performance measures as prescribed by GAAP.
In this news release, the Company refers to revenue and percentage change in revenue on a comparable, constant-currency basis. Company management believes that these non-GAAP measures provide a useful way to evaluate the revenue performance of LivaNova and to compare the revenue performance of current periods to prior periods on a consistent basis. Constant-currency percent change measures the change in revenue between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.
LivaNova calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For example, forward-looking net revenue growth projections are estimated on a constant-currency basis and exclude the impact of foreign currency fluctuations. Forward-looking non-GAAP adjusted diluted earnings per share guidance excludes items such as, but not limited to, changes in fair value of certain derivatives and contingent consideration arrangements and asset impairment charges that would be included in comparable GAAP financial measures. The most directly comparable GAAP measure for adjusted free cash flow is net cash provided by operating activities. Adjusted free cash flow is defined as net cash provided by operating activities less cash used for the purchase of property, plant, and equipment excluding the impact of 3T litigation settlement payments, cybersecurity incident insurance proceeds, SNIA environmental liability and related financing costs, contingent consideration payments classified within operating cash flows, and gains related to dividends received from investments and further adjusted as needed for other charges, expenses, or gains that may not be indicative of the Company’s operational performance. However, non-GAAP financial adjustments on a forward-looking basis are subject to uncertainty and variability as they are dependent on many factors, including but not limited to, the effect of foreign currency exchange fluctuations, impacts from potential acquisitions or divestitures, the ultimate outcome of legal proceedings, gains or losses on the potential sale of businesses or other assets, restructuring costs, merger and integration activities, changes in fair value of derivatives, and contingent consideration arrangements, 4 asset impairment charges and the tax impact of the aforementioned items, tax law changes, or other tax matters. Accordingly, the Company does not reconcile non- GAAP financial measures on a forward-looking basis as it is impractical to do so without unreasonable effort.
Adjusted financial measures such as adjusted cost of sales, adjusted gross profit, adjusted selling, general, and administrative expense, adjusted research and development expense, adjusted other operating expense, adjusted operating income, adjusted income before income tax, adjusted income tax expense, adjusted net income, and adjusted diluted earnings per share are measures that LivaNova generally uses to facilitate management review of the operational performance of the company, to serve as a basis for strategic planning, and in the design of incentive compensation plans. Additionally, the Company uses the non-GAAP liquidity measure adjusted free cash flow. The Company believes that the presentation of these adjusted financial measures allows investors to evaluate the Company’s operational performance for different periods on a more comparable and consistent basis, and with other medical technology companies by adjusting for items that are not related to the operational performance of the Company or incurred in the ordinary course of business.
Certain statements in this news release, other than statements of historical or current fact, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects, or future events, and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. Generally, forward-looking statements can be identified by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and shareholders should not place undue reliance on forward- looking statements. There are a number of risks, uncertainties, and other important factors, many of which are beyond the Company’s control, that could cause the Company’s actual results to differ materially from the forward-looking statements contained in this news release, and include, but are not limited to, the following risks and uncertainties: risks associated with doing business globally, including volatility in the global market and worldwide economic conditions; adverse changes 5 in export and import costs and other trade restrictions as well as uncertainty over global tariffs; risks relating to supply chain pressures; failure to protect, maintain, or upgrade LivaNova’s IT systems or products, or safeguard against cybersecurity incidents, service disruptions, or data corruption; costs of complying with privacy and security of personal information requirements and laws; changes in technology, including the development of superior or alternative technology or devices by competitors and/or competition from providers of alternative medical therapies; risks related to AI integration and regulation; failure of investments, alliances, supply agreements, acquisitions, or divestitures to achieve expected returns; failure to maintain appropriate working relationships with healthcare professionals to aid in the continuing development of products; the risk of quality issues and the impacts thereof; risks relating to recalls, replacement of inventory, enforcement actions, or product liability claims; failure to comply with, or changes in, laws, regulations, or administrative practices affecting government regulation of the Company’s products; failure to retain talent, maintain an effective succession plan, and negotiate successfully with local works councils; failure to obtain or maintain approvals, clearance, or reimbursement in relation to the Company’s products; unfavorable results from clinical studies or failure to meet milestones; global healthcare policy changes that may lead to restricted access and pricing as well as payback requirements and limited reimbursement; failure to comply with rules relating to healthcare goods and services as well as anti- bribery laws; the unfavorable impact of pending or existing climate change; product liability, intellectual property, shareholder-related, environmental- related, income tax, and other litigation, disputes, losses, and costs, including in the case of the Company’s 3T Heater-Cooler litigation; risks associated with environmental laws and regulations as well as environmental liabilities, violations, and litigation, including in the case of Saluggia and SNIA; failure to protect the Company’s proprietary intellectual property; changes in tax laws and regulations, including exposure to additional income tax liabilities; risks relating to the Company’s indebtedness; risks associated with potential government shutdowns; the potential for impairments of intangible assets, goodwill, and other long-lived assets; risks associated with public health crises; risks associated with shareholder activism; effectiveness of the Company’s internal controls over financial reporting; changes in the Company’s profitability and/or failure to manage costs and expenses; fluctuations in future quarterly operating results and/or variations in revenue and operating expenses relative to estimates; and other unknown or unpredictable factors that could harm the Company’s financial performance.
The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the U.S. Securities and Exchange Commission by LivaNova.
Readers are cautioned not to place undue reliance on the Company’s forward- looking statements, which speak only as of the date of this news release. The Company undertakes no obligation to update publicly any of the 6 forward-looking statements in this news release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If LivaNova updates one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements.
(1) “Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. Excluding Europe and the U.S., “Rest of World” includes all other countries where LivaNova operates.
(2) “Other revenue” includes rental and site services income not allocated to segments. In addition, for 2025, “Other revenue” includes $3.1 million from a reduction in the reserve associated with the Italian MedTech payback measure related to product sales of previously divested businesses.
(1) “Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. Excluding Europe and the U.S., “Rest of World” includes all other countries where LivaNova operates.
(2) “Other revenue” includes rental and site services income not allocated to segments. In addition, for 2025, “Other revenue” includes $3.1 million from a reduction in the reserve associated with the Italian MedTech payback measure related to product sales of previously divested businesses.
LIVANOVA PLC AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME - UNAUDITED (In millions, except for per share amounts) Three Months Ended September 30, 2026 2025 Net revenue $393.1 $357.8 Cost of sales 128.1 112.9 Gross profit 265.1 244.9 Operating expenses: Selling, general, and 154.9 138.5 administrative Research and 47.7 48.6 development Other operating expense 34.0 3.7 Operating income 28.4 54.0 SNIA environmental — -1.7 liability expense Interest expense -8.0 -10.9 Foreign exchange and other 26.3 -7.5 income/(expense) Income before income 46.8 33.9 tax Income tax expense 12.4 7.1 Loss from equity method -0.1 — investments Net income $34.3 $26.8 Earnings per share:(1) Basic $0.62 $0.49 Diluted $0.11 $0.49 Weighted average shares outstanding: Basic 55.1 54.6 Diluted 57.4 55.2
(1) For additional details, refer to the computation of basic and diluted earnings (loss) per share further in this news release.
• Numbers may not add precisely due to rounding. 10 Adjusted Financial Measures (in millions, except for per share amounts) - Unaudited
Three Months Ended September 30, 2026 2025 Adjusted SG&A $135.7 $122.8 Adjusted R&D 44.7 45.0 Adjusted operating income 92.3 80.4 Adjusted net income 70.7 61.4 Adjusted diluted earnings per $1.23 $1.11 share
LIVANOVA PLC AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - UNAUDITED (In millions, except for per share amounts) Nine Months Ended September 30, 2026 2025 Net revenue $1,146.0 $1,027.1 Cost of sales 363.5 327.0 Gross profit 782.5 700.1 Operating expenses: Selling, general, and 456.6 405.4 administrative Research and 160.0 133.6 development Other operating 46.4 4.2 expense Operating income 119.4 156.8 SNIA environmental — -363.8 liability expense Interest expense -23.4 -41.1 Foreign exchange and other -3.2 -0.3 income/(expense) Income (loss) before 92.7 -248.4 income tax Income tax (benefit) -73.5 24.9 expense Loss from equity -1.0 — method investments Net income (loss) $165.2 -$273.4 Earnings (loss) per share:(1) Basic $3.01 -$5.01 Diluted $2.93 -$5.01 Weighted average shares outstanding: Basic 54.9 54.5 Diluted 56.3 54.5
(1) For additional details, refer to the computation of basic and diluted earnings (loss) per share further in this news release.
• Numbers may not add precisely due to rounding. 12 Adjusted Financial Measures (in millions, except for per share amounts) - Unaudited
Nine Months Ended September 30, 2026 2025 Adjusted SG&A $401.3 $359.9 Adjusted R&D 141.8 127.2 Adjusted operating income 254.1 222.3 Adjusted net income 196.2 166.9 Adjusted diluted earnings per $3.48 $3.04 share
(2) Mark-to-market adjustments for the 2029 Notes embedded and capped call derivatives, and non-cash interest expense
(3) Remeasurement of contingent consideration related to the ImThera acquisition
(4) 3T Heater-Cooler litigation provision, and legal expenses primarily related to 3T Heater-Cooler defense
(6) The impact of valuation allowances, discrete tax items, the tax impact of intercompany transactions, and the tax impact on non-GAAP adjustments
(3) Mark-to-market adjustments for the 2025 and 2029 Notes embedded and capped call derivatives, and non-cash interest expense
(4) Remeasurement of contingent consideration related to the ImThera acquisition
(5) Legal expenses primarily related to 3T Heater-Cooler defense, 3T Heater- Cooler litigation provision, and SNIA environmental liability
(7) The impact of valuation allowances, discrete tax items, the tax impact of intercompany transactions, and the tax impact on non-GAAP adjustments
(2) Gain on sale of investment, partially offset by impairment of investment without readily determinable fair value
(3) Mark-to-market adjustments for the 2029 Notes embedded and capped call derivatives, non-cash interest expense, and loss on debt extinguishment
(4) Remeasurement of contingent consideration related to the ImThera acquisition
(5) Legal expenses primarily related to 3T Heater-Cooler defense, 3T Heater- Cooler litigation provision, Saluggia site remediation provision, and Medical Device Regulation ("MDR") costs
(7) The impact of valuation allowances, discrete tax items, the tax impact of intercompany transactions, and the tax impact on non-GAAP adjustments
(3) Loss on investment revaluation of Ceribell, Inc. and impairment of investment in Highlife S.A.S.
(4) Mark-to-market adjustments for the 2025 and 2029 Notes embedded and capped call derivatives, interest expense on the Term Facilities, non-cash interest expense on the 2025 and 2029 Notes and Revolving Credit Facility, loss on debt extinguishment, and interest income on the collateral for the SNIA litigation guarantee and delayed draw on Term Facilities
(5) Remeasurement of contingent consideration related to the ImThera acquisition
(6) SNIA environmental liability, legal expenses primarily related to 3T Heater- Cooler defense, MDR costs, 3T Heater-Cooler litigation provision, and R&D tax incentive
(8) The impact of valuation allowances, discrete tax items, the tax impact of intercompany transactions, and the tax impact on non-GAAP adjustments
(9) The denominator used to calculate the impact of non-GAAP adjustments on a per share basis and adjusted diluted earnings per share includes dilution from LivaNova's share-based compensation awards that was excluded from the calculation of GAAP diluted loss per share because the effect would have been anti-dilutive. See the reconciliation of GAAP diluted weighted average shares outstanding, used in the computation of GAAP diluted loss per share, to adjusted diluted weighted average shares outstanding, used in the computation of adjusted diluted earnings per share, at the end of this news release.
LIVANOVA PLC AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED (In millions) September 30, December 31, 2025 2026 ASSETS Current Assets: Cash and cash $563.5 $635.6 equivalents Accounts receivable, net of 236.4 216.0 allowance Inventories 177.9 164.7 Prepaid and 46.3 48.6 refundable taxes Prepaid expenses and other current 58.9 36.8 assets Total Current 1,082.8 1,101.6 Assets Property, plant, 293.3 242.6 and equipment, net Goodwill 778.8 792.8 Intangible assets, 210.7 230.0 net Operating lease 56.7 55.5 assets Investments 16.8 20.3 Deferred tax 194.5 111.0 assets Long-term 52.6 36.6 derivative assets Other assets 26.9 15.7 Total Assets $2,713.1 $2,606.1 LIABILITIES AND SHAREHOLDERS’ EQUITY Current Liabilities: Current debt $3.9 $31.5 obligations Accounts payable 106.9 97.2 Accrued liabilities and 128.9 107.1 other SNIA environmental 383.6 396.2 liability Current contingent — 50.0 consideration Taxes payable 28.9 33.1 Accrued employee compensation and 87.9 92.9 related benefits Total Current 740.2 808.1 Liabilities Long-term debt 295.2 345.2 obligations Long-term contingent 45.4 42.0 consideration Deferred tax 7.7 9.6 liabilities Long-term operating lease 48.8 48.3 liabilities Long-term employee compensation and 13.9 13.6 related benefits Long-term derivative 124.8 83.9 liabilities Other long-term 65.1 55.4 liabilities Total Liabilities 1,341.1 1,406.1 Total Shareholders’ 1,372.1 1,200.0 Equity Total Liabilities and Shareholders’ $2,713.1 $2,606.1 Equity
LIVANOVA PLC AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED (In millions) Nine Months Ended September 30, 2026 2025 Operating Activities: Net income (loss) $165.2 -$273.4 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Deferred income tax -86.9 4.1 (benefit) expense Share-based 39.7 26.9 compensation Remeasurement of 29.4 -17.0 derivative instruments Depreciation 26.2 21.0 Amortization of 17.6 13.2 intangible assets Amortization of debt 14.8 17.3 issuance costs Remeasurement of contingent 13.8 5.5 consideration to fair value Gain on sale of -13.6 — investment Amortization of 7.8 10.7 operating lease assets Impairment of 1.1 1.1 investment Loss on debt 0.9 2.7 extinguishment Loss on investment revaluation - — 3.6 Ceribell, Inc. Other, net 0.3 2.4 Changes in operating assets and liabilities: Accounts receivable, -22.5 -5.8 net Inventories -15.4 -8.1 Other current and -25.8 50.6 non-current assets Accounts payable and accrued current and -14.7 -36.1 non-current liabilities Taxes payable -11.3 -13.6 Litigation provision 29.0 3.0 liability SNIA environmental — 363.8 liability Net cash provided by operating 155.5 171.9 activities Investing Activities: Purchases of property, plant, and -76.6 -48.8 equipment Proceeds from 9.1 6.5 investments Purchases of -2.1 — investments Other, net 0.1 -0.4 Net cash used in -69.6 -42.7 investing activities Financing Activities: Repayment of long-term -95.9 -216.8 debt obligations Payment of contingent -50.4 — consideration Shares repurchased from employees for -11.7 -3.6 minimum tax withholding Other, net 4.5 -2.3 Net cash used in -153.6 -222.8 financing activities Effect of exchange rate changes on cash, -4.3 16.0 cash equivalents, and restricted cash Net decrease in cash, cash equivalents, -72.1 -77.5 and restricted cash Cash, cash equivalents, and restricted 635.6 723.6 cash at beginning of period Cash and cash equivalents at end of $563.5 $646.1 period
COMPU… OF BASIC AND DILUT… EARNI… (LOSS) PER SHARE - UNAUD… (In milli… except for per share amoun… Three Nine Months Months Ended Ended Septem… Septemb… 30, 30, 2026 2025 2026 2025 Numer… Net income (loss) $34.3 $26.8 $165.2 -$273.4 - basic Less: Gain on 2029 Notes conve… option -28.2 — — — change in fair value, net of tax(1) Net income (loss) $6.1 $26.8 $165.2 -$273.4 - dilut… Denom… Basic weigh… avera… 55.1 54.6 54.9 54.5 shares outst… Add: Dilut… effect 1.6 0.5 1.4 — of share… compe… Add: Dilut… effect of 0.6 — — — conve… debt instr… Dilut… weigh… avera… 57.4 55.2 56.3 54.5 shares outst… Earni… (Loss) Per Share: Basic $0.62 $0.49 $3.01 -$5.01 Dilut… $0.11 $0.49 $2.93 -$5.01
(1) For the three months ended September 30, 2025, and for the nine months ended September 30, 2026 and 2025, the 2029 Notes were outstanding and potentially dilutive securities but were excluded from the computation of diluted earnings (loss) per share because their effect would have been anti-dilutive under the if-converted method.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED Three Months Ended September 30, (In millions) 2026 ────────────────────────────────────────────────────────────────────────────── Net cash provided by operating $73.7 activities Less: Purchases of property, plant, and -30.8 equipment Add: 3T Heater-Cooler litigation 12.9 payments Adjusted free cash flow $55.8
The following table presents the reconciliation of GAAP diluted weighted average shares outstanding, used in the computation of GAAP diluted loss per share, to adjusted diluted weighted average shares outstanding, used in the computation of adjusted diluted earnings per share:
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - UNAUDITED Nine Months Ended (In millions) September 30, 2025 ────────────────────────────────────────────────────────────────────────────── GAAP diluted weighted average shares 54.5 outstanding Add: Effects of share-based compensation 0.3 instruments Adjusted diluted weighted average shares 54.8 outstanding
Full text with the tables
EXHIBIT 99.1
NEWS RELEASE
LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and
Adjusted Diluted EPS Guidance
– Delivered 9.9% reported and 10.0% constant-currency revenue growth
– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance
(1)
– Achieved a key milestone in scaling oxygenator production capacity with the
operational launch of a dedicated manufacturing line
GLOUCESTER, United Kingdom, November 4, 2026 — LivaNova PLC (Nasdaq: LIVN), a
market-leading medical technology company, today reported results for the third
quarter ended September 30, 2026 and raised full-year 2026 guidance.
Financial Summary and Highlights (1)
• Third-quarter revenue of $393.1 million increased 9.9% on a reported basis and
10.0% on a constant-currency basis as compared to the prior-year period
• Third-quarter U.S. GAAP diluted earnings per share of $0.11 and adjusted
diluted earnings per share of $1.23
• Third-quarter net cash provided by operating activities of $73.7 million and
adjusted free cash flow of $55.8 million
• Raised full-year 2026 revenue growth range by 100 basis points to 9% to 10% on
a constant-currency basis. Raised full-year 2026 adjusted diluted earnings per
share range by $0.10 at midpoint to $4.40 to $4.50. Maintained full-year 2026
adjusted free cash flow range of $140 million to $160 million
• Achieved operational production on previously announced new oxygenator
manufacturing line, representing an important milestone in expanding production
capacity to address strong customer demand
• In October 2026, the American Medical Association CPT® Editorial Panel
announced the establishment of new Category I Current Procedural Terminology
(CPT®) codes that include LivaNova’s proximal hypoglossal nerve stimulation
therapy for the treatment of moderate to severe obstructive sleep apnea, with an
expected effective date of January 1, 2028
• In October 2026, announced the publication of the full 36-month results from
the CORE-VNS study, the largest prospective, international study evaluating
contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy, in
Neuromodulation demonstrating a 76% median reduction in seizure frequency and a
durable clinical benefit
(1) Constant-currency percent change, adjusted diluted earnings per share, and
adjusted free cash flow are non-GAAP measures. Constant-currency percent change
excludes the impact from fluctuations in the various currencies in which the
Company operates as compared to reported percent change. For an explanation of
these and other non-GAAP measures used in this news release, see the section
entitled "Use of Non-GAAP Financial Measures." For reconciliations of certain
non-GAAP measures, see the tables that accompany this news release. As discussed
in the section entitled "Use of Non-GAAP Financial Measures" below, the Company
is unable to predict with a reasonable degree of certainty the type and extent
of certain items that would be expected to impact GAAP measures but would not
impact the non-GAAP measures. Accordingly, the Company is unable to reconcile
forward-looking non-GAAP financial measures to their most directly comparable
forward-looking GAAP financial measures without unreasonable efforts.
1
“Our team continues to deliver robust revenue growth driven by commercial
execution and healthy global demand for our Cardiopulmonary and Epilepsy
technologies,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova.
“We also made meaningful progress against key milestones, positioning us to
address significant market demand while expanding patient access to care. Our
updated 2026 guidance reflects confidence across the portfolio as we advance our
strategic priorities, drive innovation to address important unmet patient needs,
and remain focused on delivering long-term shareholder value.”
Third-Quarter 2026 Results
The following table summarizes net revenue by segment (in millions):
Three
Mont… % Cons…
Ended Chan… %
Sept… Chan…
30,
2026 2025
Car… $225… $203… 10.9 % 10.9 %
Neu… 166.1 149.5 11.1 % 11.2 %
Oth… 1.7 5.0 -65.7 % -65… %
Rev…
Tot… $393… $357… 9.9 % 10.0 %
Com…
(1) “Other revenue” includes rental and site services income not allocated to
segments. In addition, for 2025, “Other revenue” includes $3.1 million from a
reduction in the reserve associated with the Italian MedTech payback measure
related to product sales of previously divested businesses.
• Numbers may not add precisely due to rounding.
Third-quarter 2026 Cardiopulmonary revenue increased 10.9% on a reported basis
and 10.9% on a constant-currency basis versus the third quarter of 2025 with
growth across all regions, driven by strong consumables demand and Essenz™
Perfusion System sales, as well as favorable realized price.
Third-quarter 2026 Neuromodulation revenue increased 11.1% on a reported basis
and 11.2% on a constant-currency basis versus the third quarter of 2025 with
growth across all regions, driven by higher volume and favorable realized price.
Earnings Analysis
On a U.S. GAAP basis, third-quarter 2026 operating income was $28.4 million, as
compared to operating income of $54.0 million for the third quarter of 2025.
Adjusted operating income for the third quarter of 2026 was $92.3 million, as
compared to adjusted operating income of $80.4 million for the third quarter of
2025.
On a U.S. GAAP basis, third-quarter 2026 diluted earnings per share was $0.11 as
compared to diluted earnings per share of $0.49 in the third quarter of 2025.
Third-quarter 2026 adjusted diluted earnings per share was $1.23, as compared to
adjusted diluted earnings per share of $1.11 in the third quarter of 2025.
2
Full-Year 2026 Guidance
LivaNova now expects full-year 2026 revenue to grow between 9% and 10% (versus
8% and 9% prior) on a constant-currency basis. Foreign currency is expected to
be a tailwind of approximately 1% based on current exchange rates, consistent
with prior guidance.
Adjusted diluted earnings per share for 2026 is now expected to be in the range
of $4.40 to $4.50 (versus $4.30 to $4.40 prior), assuming a share count of
approximately 56 million for full-year 2026. In 2026, the Company estimates
adjusted free cash flow in the range of $140 million to $160 million, consistent
with prior guidance.
As discussed in the section entitled “Use of Non-GAAP Financial Measures” below,
the Company is unable to predict with a reasonable degree of certainty the type
and extent of certain items that would be expected to impact GAAP measures but
would not impact the non-GAAP measures. Accordingly, the Company is unable to
reconcile the forward-looking non-GAAP financial measures included in this
section to their most directly comparable forward-looking GAAP financial
measures without unreasonable efforts.
Audiocast and Conference Call Instructions
The Company will host a live audiocast at 1 p.m. London time (8 a.m. Eastern
Standard Time) on Wed., November 4, 2026 that will be accessible at
www.livanova.com/events . Listeners should register in advance and log on
approximately 10 minutes early to ensure proper setup. To listen to the
conference call by telephone, dial +1 833 461 5787 (if dialing from within the
U.S.) or +1 585 542 9983 (if dialing from outside the U.S.). The conference call
meeting ID is 495924914. Within 24 hours of the audiocast, a replay will be
available at www.livanova.com/events , where it will be archived and accessible
for approximately 90 days.
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades
of experience with a vision to change the trajectory of lives for a new day.
Through ingenious medical solutions in select neurological and cardiac
conditions, LivaNova strives to ignite patient turnarounds. With its registered
office in the United Kingdom, approximately 3,300 employees, and a presence in
more than 100 countries, LivaNova serves patients, healthcare professionals, and
healthcare systems worldwide. For more information, please visit
www.livanova.com .
3
Use of Non-GAAP Financial Measures
To supplement financial measures presented in accordance with generally accepted
accounting principles in the United States (U.S. GAAP or GAAP), management has
disclosed certain additional measures not presented in accordance with GAAP
known as “non-GAAP financial measures” or “adjusted financial measures.” Company
management uses these non-GAAP measures to monitor the Company’s operational
performance and for benchmarking against other medical technology companies.
Non-GAAP financial measures used by the Company may be calculated differently
from, and therefore may not be comparable to, similarly titled measures used by
other companies. These non-GAAP financial measures should be considered along
with, but not as alternatives to, operational performance measures as prescribed
by GAAP.
In this news release, the Company refers to revenue and percentage change in
revenue on a comparable, constant-currency basis. Company management believes
that these non-GAAP measures provide a useful way to evaluate the revenue
performance of LivaNova and to compare the revenue performance of current
periods to prior periods on a consistent basis. Constant-currency percent change
measures the change in revenue between current and prior-year periods using
average exchange rates in effect during the applicable prior-year period.
LivaNova calculates forward-looking non-GAAP financial measures based on
internal forecasts that omit certain amounts that would be included in GAAP
financial measures. For example, forward-looking net revenue growth projections
are estimated on a constant-currency basis and exclude the impact of foreign
currency fluctuations. Forward-looking non-GAAP adjusted diluted earnings per
share guidance excludes items such as, but not limited to, changes in fair value
of certain derivatives and contingent consideration arrangements and asset
impairment charges that would be included in comparable GAAP financial measures.
The most directly comparable GAAP measure for adjusted free cash flow is net
cash provided by operating activities. Adjusted free cash flow is defined as net
cash provided by operating activities less cash used for the purchase of
property, plant, and equipment excluding the impact of 3T litigation settlement
payments, cybersecurity incident insurance proceeds, SNIA environmental
liability and related financing costs, contingent consideration payments
classified within operating cash flows, and gains related to dividends received
from investments and further adjusted as needed for other charges, expenses, or
gains that may not be indicative of the Company’s operational performance.
However, non-GAAP financial adjustments on a forward-looking basis are subject
to uncertainty and variability as they are dependent on many factors, including
but not limited to, the effect of foreign currency exchange fluctuations,
impacts from potential acquisitions or divestitures, the ultimate outcome of
legal proceedings, gains or losses on the potential sale of businesses or other
assets, restructuring costs, merger and integration activities, changes in fair
value of derivatives, and contingent consideration arrangements,
4
asset impairment charges and the tax impact of the aforementioned items, tax law
changes, or other tax matters. Accordingly, the Company does not reconcile non-
GAAP financial measures on a forward-looking basis as it is impractical to do so
without unreasonable effort.
Adjusted financial measures such as adjusted cost of sales, adjusted gross
profit, adjusted selling, general, and administrative expense, adjusted research
and development expense, adjusted other operating expense, adjusted operating
income, adjusted income before income tax, adjusted income tax expense, adjusted
net income, and adjusted diluted earnings per share are measures that LivaNova
generally uses to facilitate management review of the operational performance of
the company, to serve as a basis for strategic planning, and in the design of
incentive compensation plans. Additionally, the Company uses the non-GAAP
liquidity measure adjusted free cash flow. The Company believes that the
presentation of these adjusted financial measures allows investors to evaluate
the Company’s operational performance for different periods on a more comparable
and consistent basis, and with other medical technology companies by adjusting
for items that are not related to the operational performance of the Company or
incurred in the ordinary course of business.
Safe Harbor Statement
Certain statements in this news release, other than statements of historical or
current fact, are “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and
Section 21E of the Exchange Act. These statements include, but are not limited
to, LivaNova’s plans, objectives, strategies, financial performance and outlook,
trends, the amount and timing of future cash distributions, prospects, or future
events, and involve known and unknown risks that are difficult to predict. As a
result, the Company’s actual financial results, performance, achievements, or
prospects may differ materially from those expressed or implied by these
forward-looking statements. Generally, forward-looking statements can be
identified by the use of words such as “may,” “could,” “seek,” “guidance,”
“predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,”
“anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee,” or variations
of these terms and similar expressions, or the negative of these terms or
similar expressions. Such forward-looking statements are necessarily based on
estimates and assumptions that, while considered reasonable by LivaNova and its
management based on their knowledge and understanding of the business and
industry, are inherently uncertain. These statements are not guarantees of
future performance, and shareholders should not place undue reliance on forward-
looking statements. There are a number of risks, uncertainties, and other
important factors, many of which are beyond the Company’s control, that could
cause the Company’s actual results to differ materially from the forward-looking
statements contained in this news release, and include, but are not limited to,
the following risks and uncertainties: risks associated with doing business
globally, including volatility in the global market and worldwide economic
conditions; adverse changes
5
in export and import costs and other trade restrictions as well as uncertainty
over global tariffs; risks relating to supply chain pressures; failure to
protect, maintain, or upgrade LivaNova’s IT systems or products, or safeguard
against cybersecurity incidents, service disruptions, or data corruption; costs
of complying with privacy and security of personal information requirements and
laws; changes in technology, including the development of superior or
alternative technology or devices by competitors and/or competition from
providers of alternative medical therapies; risks related to AI integration and
regulation; failure of investments, alliances, supply agreements, acquisitions,
or divestitures to achieve expected returns; failure to maintain appropriate
working relationships with healthcare professionals to aid in the continuing
development of products; the risk of quality issues and the impacts thereof;
risks relating to recalls, replacement of inventory, enforcement actions, or
product liability claims; failure to comply with, or changes in, laws,
regulations, or administrative practices affecting government regulation of the
Company’s products; failure to retain talent, maintain an effective succession
plan, and negotiate successfully with local works councils; failure to obtain or
maintain approvals, clearance, or reimbursement in relation to the Company’s
products; unfavorable results from clinical studies or failure to meet
milestones; global healthcare policy changes that may lead to restricted access
and pricing as well as payback requirements and limited reimbursement; failure
to comply with rules relating to healthcare goods and services as well as anti-
bribery laws; the unfavorable impact of pending or existing climate change;
product liability, intellectual property, shareholder-related, environmental-
related, income tax, and other litigation, disputes, losses, and costs,
including in the case of the Company’s 3T Heater-Cooler litigation; risks
associated with environmental laws and regulations as well as environmental
liabilities, violations, and litigation, including in the case of Saluggia and
SNIA; failure to protect the Company’s proprietary intellectual property;
changes in tax laws and regulations, including exposure to additional income tax
liabilities; risks relating to the Company’s indebtedness; risks associated with
potential government shutdowns; the potential for impairments of intangible
assets, goodwill, and other long-lived assets; risks associated with public
health crises; risks associated with shareholder activism; effectiveness of the
Company’s internal controls over financial reporting; changes in the Company’s
profitability and/or failure to manage costs and expenses; fluctuations in
future quarterly operating results and/or variations in revenue and operating
expenses relative to estimates; and other unknown or unpredictable factors that
could harm the Company’s financial performance.
The foregoing list of factors is not exhaustive. You should carefully consider
the foregoing factors and the other risks and uncertainties that affect the
Company’s business, including those described in the “Risk Factors” section of
the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports
on Form 8-K and other documents filed from time to time with the U.S. Securities
and Exchange Commission by LivaNova.
Readers are cautioned not to place undue reliance on the Company’s forward-
looking statements, which speak only as of the date of this news release. The
Company undertakes no obligation to update publicly any of the
6
forward-looking statements in this news release to reflect actual results, new
information or future events, changes in assumptions or changes in other factors
affecting forward-looking statements, except to the extent required by
applicable law. If LivaNova updates one or more forward-looking statements, no
inference should be drawn that the Company will make additional updates with
respect to those or other forward-looking statements.
VNS Therapy and Essenz are trademarks of LivaNova USA, Inc.
Briana Gotlin
Vice President, Investor Relations
Phone: +1 281 895 2382
e-mail: [email protected]
7
LIVA…
PLC
NET
REVE…
-
UNAU…
(In
mill…
Three
Mont…
Ended
Sept…
30,
% Cons…
2026 2025 Change %
Chan…
Card…
U.S. $80.4 $71.9 11.8 % 11.8 %
Euro… 57.1 50.1 14.0 % 15.9 %
Rest
of 87.8 81.2 8.1 % 7.1 %
Worl…
225.3 203.2 10.9 % 10.9 %
Neur…
U.S. 130.7 118.4 10.4 % 10.4 %
Euro… 16.6 14.5 14.4 % 15.5 %
Rest
of 18.8 16.6 13.0 % 12.9 %
Worl…
166.1 149.5 11.1 % 11.2 %
Other 1.7 5.0 -65.7 % -65.2 %
reve…
Total
Comp…
U.S. 211.1 190.4 10.9 % 10.9 %
Euro… 73.7 67.7 8.8 % 10.5 %
Rest
of 108.3 99.6 8.7 % 7.9 %
Worl…
$393.1 $357… 9.9 % 10.0 %
(1) “Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain,
Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and
Denmark. Excluding Europe and the U.S., “Rest of World” includes all other
countries where LivaNova operates.
(2) “Other revenue” includes rental and site services income not allocated to
segments. In addition, for 2025, “Other revenue” includes $3.1 million from a
reduction in the reserve associated with the Italian MedTech payback measure
related to product sales of previously divested businesses.
• Numbers may not add precisely due to rounding.
8
LIVA…
PLC
NET
REVE…
-
UNAU…
(In
mill…
Nine
Mont…
Ended
Sept…
30,
% Cons…
2026 2025 Change %
Chan…
Card…
U.S. $222.5 $204… 9.0 % 9.0 %
Euro… 176.3 143.6 22.8 % 19.1 %
Rest
of 256.7 231.2 11.1 % 9.0 %
Worl…
655.5 578.8 13.3 % 11.5 %
Neur…
U.S. 372.7 344.0 8.4 % 8.4 %
Euro… 54.8 47.4 15.5 % 11.4 %
Rest
of 57.4 48.7 17.8 % 15.6 %
Worl…
484.9 440.1 10.2 % 9.5 %
Other 5.6 8.2 -32.0 % -34.4 %
reve…
Total
Comp…
U.S. 595.2 548.1 8.6 % 8.6 %
Euro… 231.1 194.2 19.0 % 15.3 %
Rest
of 319.7 284.9 12.2 % 10.1 %
Worl…
$1,14… $1,0… 11.6 % 10.3 %
(1) “Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain,
Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and
Denmark. Excluding Europe and the U.S., “Rest of World” includes all other
countries where LivaNova operates.
(2) “Other revenue” includes rental and site services income not allocated to
segments. In addition, for 2025, “Other revenue” includes $3.1 million from a
reduction in the reserve associated with the Italian MedTech payback measure
related to product sales of previously divested businesses.
• Numbers may not add precisely due to rounding.
9
LIVANOVA PLC AND
SUBSIDIARIES
CONDENSED CONSOLIDATED
STATEMENTS OF
INCOME - UNAUDITED
(In millions, except
for per share
amounts)
Three Months Ended
September 30,
2026 2025
Net revenue $393.1 $357.8
Cost of sales 128.1 112.9
Gross profit 265.1 244.9
Operating expenses:
Selling, general, and 154.9 138.5
administrative
Research and 47.7 48.6
development
Other operating expense 34.0 3.7
Operating income 28.4 54.0
SNIA environmental — -1.7
liability expense
Interest expense -8.0 -10.9
Foreign exchange and
other 26.3 -7.5
income/(expense)
Income before income 46.8 33.9
tax
Income tax expense 12.4 7.1
Loss from equity method -0.1 —
investments
Net income $34.3 $26.8
Earnings per share:(1)
Basic $0.62 $0.49
Diluted $0.11 $0.49
Weighted average shares
outstanding:
Basic 55.1 54.6
Diluted 57.4 55.2
(1) For additional details, refer to the computation of basic and diluted
earnings (loss) per share further in this news release.
• Numbers may not add precisely due to rounding.
10
Adjusted Financial Measures (in millions, except for per share amounts) -
Unaudited
Three Months Ended
September 30,
2026 2025
Adjusted SG&A $135.7 $122.8
Adjusted R&D 44.7 45.0
Adjusted operating income 92.3 80.4
Adjusted net income 70.7 61.4
Adjusted diluted earnings per $1.23 $1.11
share
Statistics (as a % of net revenue, except for income tax rate) - Unaudited
GAAP Adjus…
Three Three
Mont… Months
Ended Ended
Sept… Septe…
30, 30,
2026 2025 2026 2025
Gross 67.4 % 68.4 % 69.3 % 69.4 %
prof…
SG&A 39.4 % 38.7 % 34.5 % 34.3 %
R&D 12.1 % 13.6 % 11.4 % 12.6 %
Oper… 7.2 % 15.1 % 23.5 % 22.5 %
inco…
Net 8.7 % 7.5 % 18.0 % 17.2 %
inco…
Inco…
tax 26.5 % 21.0 % 23.3 % 22.1 %
rate
11
LIVANOVA PLC AND
SUBSIDIARIES
CONDENSED CONSOLIDATED
STATEMENTS OF
INCOME (LOSS) -
UNAUDITED
(In millions, except
for per share
amounts)
Nine Months Ended
September 30,
2026 2025
Net revenue $1,146.0 $1,027.1
Cost of sales 363.5 327.0
Gross profit 782.5 700.1
Operating expenses:
Selling, general, and 456.6 405.4
administrative
Research and 160.0 133.6
development
Other operating 46.4 4.2
expense
Operating income 119.4 156.8
SNIA environmental — -363.8
liability expense
Interest expense -23.4 -41.1
Foreign exchange and
other -3.2 -0.3
income/(expense)
Income (loss) before 92.7 -248.4
income tax
Income tax (benefit) -73.5 24.9
expense
Loss from equity -1.0 —
method investments
Net income (loss) $165.2 -$273.4
Earnings (loss) per
share:(1)
Basic $3.01 -$5.01
Diluted $2.93 -$5.01
Weighted average
shares outstanding:
Basic 54.9 54.5
Diluted 56.3 54.5
(1) For additional details, refer to the computation of basic and diluted
earnings (loss) per share further in this news release.
• Numbers may not add precisely due to rounding.
12
Adjusted Financial Measures (in millions, except for per share amounts) -
Unaudited
Nine Months Ended
September 30,
2026 2025
Adjusted SG&A $401.3 $359.9
Adjusted R&D 141.8 127.2
Adjusted operating income 254.1 222.3
Adjusted net income 196.2 166.9
Adjusted diluted earnings per $3.48 $3.04
share
Statistics (as a % of net revenue, except for income tax rate) - Unaudited
GAAP Adju…
Nine Nine
Mont… Mont…
Ended Ended
Sept… Sept…
30, 30,
2026 2025 2026 2025
Gro… 68.3 % 68.2 % 69.6 % 69.1 %
pro…
SG&A 39.8 % 39.5 % 35.0 % 35.0 %
R&D 14.0 % 13.0 % 12.4 % 12.4 %
Ope… 10.4 % 15.3 % 22.2 % 21.6 %
inc…
Net
inc… 14.4 % -26.6 % 17.1 % 16.3 %
(lo…
Inc…
tax -79.2 % -10.0 % 22.7 % 22.7 %
rate
13
…
…
… …
… … … … … … …
… … … … & … …
… … … … … …
…
… … … … … … … …
… % … % — % … % — % … % — % …
… … — — … … — …
… % … % — % — % … % … % — % …
… — — — … … — …
… % — % — % — % … % … % — % …
… — — — … — — —
… … — … … … — …
… % … % — % … % … % … % — % …
… … … … … … … …
… % … % … % … % … % … % … % …
… … … … … … … …
GAAP results for the three months ended September 30, 2026 include:
(1) Depreciation and amortization associated with purchase price accounting
(2) Mark-to-market adjustments for the 2029 Notes embedded and capped call
derivatives, and non-cash interest expense
(3) Remeasurement of contingent consideration related to the ImThera acquisition
(4) 3T Heater-Cooler litigation provision, and legal expenses primarily related
to 3T Heater-Cooler defense
(5) Non-cash expenses associated with share-based compensation costs
(6) The impact of valuation allowances, discrete tax items, the tax impact of
intercompany transactions, and the tax impact on non-GAAP adjustments
• Numbers may not add precisely due to rounding.
14
…
…
… …
… … … … …
… … … & …
… … … … …
…
… … … … …
… % — % … % … % …
… — — … …
… % — % — % … % …
… — … … …
… % — % … % … % …
… — — — —
… — … … …
… % — % … % … % …
… … … … …
… % … % … % … % …
… … … … …
GAAP results for the three months ended September 30, 2025 include:
(1) Depreciation and amortization associated with purchase price accounting
(2) Impairment of investment in Highlife S.A.S.
(3) Mark-to-market adjustments for the 2025 and 2029 Notes embedded and capped
call derivatives, and non-cash interest expense
(4) Remeasurement of contingent consideration related to the ImThera acquisition
(5) Legal expenses primarily related to 3T Heater-Cooler defense, 3T Heater-
Cooler litigation provision, and SNIA environmental liability
(6) Non-cash expenses associated with share-based compensation costs
(7) The impact of valuation allowances, discrete tax items, the tax impact of
intercompany transactions, and the tax impact on non-GAAP adjustments
• Numbers may not add precisely due to rounding.
15
…
…
… …
… … … … …
… … … & …
… … … … …
…
… … … … … …
… % … % — % … % … % …
… … — — … …
… % … % — % — % … % …
… … — … … …
… % — % — % … % … % …
… — — — — —
… … — … … …
… % … % — % … % … % …
… … … … … …
… % … % … % … % … % …
… … … … … …
GAAP results for the nine months ended September 30, 2026 include:
(1) Depreciation and amortization associated with purchase price accounting
(2) Gain on sale of investment, partially offset by impairment of investment
without readily determinable fair value
(3) Mark-to-market adjustments for the 2029 Notes embedded and capped call
derivatives, non-cash interest expense, and loss on debt extinguishment
(4) Remeasurement of contingent consideration related to the ImThera acquisition
(5) Legal expenses primarily related to 3T Heater-Cooler defense, 3T Heater-
Cooler litigation provision, Saluggia site remediation provision, and Medical
Device Regulation ("MDR") costs
(6) Non-cash expenses associated with share-based compensation costs
(7) The impact of valuation allowances, discrete tax items, the tax impact of
intercompany transactions, and the tax impact on non-GAAP adjustments
• Numbers may not add precisely due to rounding.
16
…
… … …
… & …
… … …
…
… … …
% … % … % …
— … …
% — % … % …
… … …
% … % … % …
— — —
… … …
% … % … % …
… … …
% … % … % …
… … …
GAAP results for the nine months ended September 30, 2025 include:
(1) Restructuring expense related to organizational changes
(2) Depreciation and amortization associated with purchase price accounting
(3) Loss on investment revaluation of Ceribell, Inc. and impairment of
investment in Highlife S.A.S.
(4) Mark-to-market adjustments for the 2025 and 2029 Notes embedded and capped
call derivatives, interest expense on the Term Facilities, non-cash interest
expense on the 2025 and 2029 Notes and Revolving Credit Facility, loss on debt
extinguishment, and interest income on the collateral for the SNIA litigation
guarantee and delayed draw on Term Facilities
(5) Remeasurement of contingent consideration related to the ImThera acquisition
(6) SNIA environmental liability, legal expenses primarily related to 3T Heater-
Cooler defense, MDR costs, 3T Heater-Cooler litigation provision, and R&D tax
incentive
(7) Non-cash expenses associated with share-based compensation costs
(8) The impact of valuation allowances, discrete tax items, the tax impact of
intercompany transactions, and the tax impact on non-GAAP adjustments
(9) The denominator used to calculate the impact of non-GAAP adjustments on a
per share basis and adjusted diluted earnings per share includes dilution from
LivaNova's share-based compensation awards that was excluded from the
calculation of GAAP diluted loss per share because the effect would have been
anti-dilutive. See the reconciliation of GAAP diluted weighted average shares
outstanding, used in the computation of GAAP diluted loss per share, to adjusted
diluted weighted average shares outstanding, used in the computation of adjusted
diluted earnings per share, at the end of this news release.
• Numbers may not add precisely due to rounding.
17
LIVANOVA PLC AND
SUBSIDIARIES
CONDENSED
CONSOLIDATED
BALANCE SHEETS -
UNAUDITED
(In millions)
September 30, December 31, 2025
2026
ASSETS
Current Assets:
Cash and cash $563.5 $635.6
equivalents
Accounts
receivable, net of 236.4 216.0
allowance
Inventories 177.9 164.7
Prepaid and 46.3 48.6
refundable taxes
Prepaid expenses
and other current 58.9 36.8
assets
Total Current 1,082.8 1,101.6
Assets
Property, plant, 293.3 242.6
and equipment, net
Goodwill 778.8 792.8
Intangible assets, 210.7 230.0
net
Operating lease 56.7 55.5
assets
Investments 16.8 20.3
Deferred tax 194.5 111.0
assets
Long-term 52.6 36.6
derivative assets
Other assets 26.9 15.7
Total Assets $2,713.1 $2,606.1
LIABILITIES AND
SHAREHOLDERS’
EQUITY
Current
Liabilities:
Current debt $3.9 $31.5
obligations
Accounts payable 106.9 97.2
Accrued
liabilities and 128.9 107.1
other
SNIA environmental 383.6 396.2
liability
Current contingent — 50.0
consideration
Taxes payable 28.9 33.1
Accrued employee
compensation and 87.9 92.9
related benefits
Total Current 740.2 808.1
Liabilities
Long-term debt 295.2 345.2
obligations
Long-term
contingent 45.4 42.0
consideration
Deferred tax 7.7 9.6
liabilities
Long-term
operating lease 48.8 48.3
liabilities
Long-term employee
compensation and 13.9 13.6
related benefits
Long-term
derivative 124.8 83.9
liabilities
Other long-term 65.1 55.4
liabilities
Total Liabilities 1,341.1 1,406.1
Total
Shareholders’ 1,372.1 1,200.0
Equity
Total Liabilities
and Shareholders’ $2,713.1 $2,606.1
Equity
• Numbers may not add precisely due to rounding.
18
LIVANOVA PLC AND
SUBSIDIARIES
CONDENSED CONSOLIDATED
STATEMENTS OF
CASH FLOWS - UNAUDITED
(In millions) Nine Months Ended
September 30,
2026 2025
Operating Activities:
Net income (loss) $165.2 -$273.4
Adjustments to
reconcile net income
(loss) to net cash
provided by operating
activities:
Deferred income tax -86.9 4.1
(benefit) expense
Share-based 39.7 26.9
compensation
Remeasurement of 29.4 -17.0
derivative instruments
Depreciation 26.2 21.0
Amortization of 17.6 13.2
intangible assets
Amortization of debt 14.8 17.3
issuance costs
Remeasurement of
contingent 13.8 5.5
consideration to fair
value
Gain on sale of -13.6 —
investment
Amortization of 7.8 10.7
operating lease assets
Impairment of 1.1 1.1
investment
Loss on debt 0.9 2.7
extinguishment
Loss on investment
revaluation - — 3.6
Ceribell, Inc.
Other, net 0.3 2.4
Changes in operating
assets and
liabilities:
Accounts receivable, -22.5 -5.8
net
Inventories -15.4 -8.1
Other current and -25.8 50.6
non-current assets
Accounts payable and
accrued current and -14.7 -36.1
non-current liabilities
Taxes payable -11.3 -13.6
Litigation provision 29.0 3.0
liability
SNIA environmental — 363.8
liability
Net cash provided by
operating 155.5 171.9
activities
Investing Activities:
Purchases of property,
plant, and -76.6 -48.8
equipment
Proceeds from 9.1 6.5
investments
Purchases of -2.1 —
investments
Other, net 0.1 -0.4
Net cash used in -69.6 -42.7
investing activities
Financing Activities:
Repayment of long-term -95.9 -216.8
debt obligations
Payment of contingent -50.4 —
consideration
Shares repurchased from
employees for -11.7 -3.6
minimum tax withholding
Other, net 4.5 -2.3
Net cash used in -153.6 -222.8
financing activities
Effect of exchange rate
changes on cash, -4.3 16.0
cash equivalents, and
restricted cash
Net decrease in cash,
cash equivalents, -72.1 -77.5
and restricted cash
Cash, cash equivalents,
and restricted 635.6 723.6
cash at beginning of
period
Cash and cash
equivalents at end of $563.5 $646.1
period
• Numbers may not add precisely due to rounding.
19
COMPU…
OF
BASIC
AND
DILUT…
EARNI…
(LOSS)
PER
SHARE
-
UNAUD…
(In
milli…
except
for
per
share
amoun…
Three Nine
Months Months
Ended Ended
Septem… Septemb…
30, 30,
2026 2025 2026 2025
Numer…
Net
income
(loss) $34.3 $26.8 $165.2 -$273.4
-
basic
Less:
Gain
on
2029
Notes
conve…
option -28.2 — — —
change
in
fair
value,
net of
tax(1)
Net
income
(loss) $6.1 $26.8 $165.2 -$273.4
-
dilut…
Denom…
Basic
weigh…
avera… 55.1 54.6 54.9 54.5
shares
outst…
Add:
Dilut…
effect 1.6 0.5 1.4 —
of
share…
compe…
Add:
Dilut…
effect
of 0.6 — — —
conve…
debt
instr…
Dilut…
weigh…
avera… 57.4 55.2 56.3 54.5
shares
outst…
Earni…
(Loss)
Per
Share:
Basic $0.62 $0.49 $3.01 -$5.01
Dilut… $0.11 $0.49 $2.93 -$5.01
(1) For the three months ended September 30, 2025, and for the nine months ended
September 30, 2026 and 2025, the 2029 Notes were outstanding and potentially
dilutive securities but were excluded from the computation of diluted earnings
(loss) per share because their effect would have been anti-dilutive under the
if-converted method.
• Numbers may not add precisely due to rounding.
…
…
…
…
…
…
…
-
…
…
…
T…
M…
E…
S…
3…
2… 20…
G… C… A… GA… Ce… Ad…
F… T… F… Fi… Tax Fi…
M… A… M… Me… Ad… Me…
…
… $… $— $… $… $— $…
…
…
…
… 1… 9… 2… 7… 1… 1…
…
…
…
… -… — -… — — —
…
…
… $… -… $… $… -… $…
…
…
… 2… % 2… % 2… % 2… %
…
…
…
…
…
…
…
…
-
…
…
…
N…
M…
E…
S…
3…
2… 2…
G… C… A… G… C… A…
F… T… F… F… T… F…
M… A… M… M… A… M…
…
…
… $… $— $… -$… $— $2…
…
…
…
… -… 1… 5… 24… 24… 49…
…
…
…
…
… -… — -… — — —
…
…
…
… $… -… $… -$… -$… $1…
…
…
… -… % 2… % -1… % 22… %
…
• Numbers may not add precisely due to rounding.
20
RECONCILIATION OF GAAP TO
NON-GAAP FINANCIAL MEASURES -
UNAUDITED Three Months Ended September 30,
(In millions) 2026
──────────────────────────────────────────────────────────────────────────────
Net cash provided by operating $73.7
activities
Less:
Purchases of property, plant, and -30.8
equipment
Add: 3T Heater-Cooler litigation 12.9
payments
Adjusted free cash flow $55.8
• Numbers may not add precisely due to rounding.
The following table presents the reconciliation of GAAP diluted weighted average
shares outstanding, used in the computation of GAAP diluted loss per share, to
adjusted diluted weighted average shares outstanding, used in the computation of
adjusted diluted earnings per share:
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL
MEASURES - UNAUDITED Nine Months Ended
(In millions) September 30, 2025
──────────────────────────────────────────────────────────────────────────────
GAAP diluted weighted average shares 54.5
outstanding
Add: Effects of share-based compensation 0.3
instruments
Adjusted diluted weighted average shares 54.8
outstanding
• Numbers may not add precisely due to rounding.
21